You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bortezomib and thalidomide for the first‑line treatment of multiple myeloma

  • Technology appraisal guidance
  • Reference number: TA228
  • Published:  27 July 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Multiple myeloma (first line) - bortezomib and thalidomide: appeal

An appeal has been lodged for this appraisal. Below are the papers related to this appeal.

For more information on the Technology Appraisal Appeal Process, go to the appeal hearings homepage.

  • Multiple myeloma (first line) - bortezomib and thalidomide: appeal decision

  • Multiple myeloma (first line) - bortezomib and thalidomide: background information

  • Multiple myeloma (first line) - bortezomib and thalidomide: notice of appeal

  • Multiple myeloma (first line) - bortezomib and thalidomide: appeal registration

  • Multiple myeloma (first line) - bortezomib and thalidomide: appeal announcement


This page was last updated: 12 January 2011

Back to top